Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254278 · ClinicalTrials.gov registry record · Phase 2
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
A Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 316
- Enrollment target
- 20
- Study locations
NCT02254278: Completed Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma, sponsored by NRG Oncology.
NCT02254278 is a Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma that has completed, run by NRG Oncology. The registered enrollment target is 316 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02254278, a Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 316 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether IMRT is more effective with or without cisplatin in treating patients with oropharyngeal cancer.
Primary Outcome
Progression is defined as local, regional, or distant disease progression or death due to any cause. Percentage is estimated using the binomial distribution.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION IMRT 6 weeks
- RADIATION IMRT 5 weeks
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills-Peninsula Medical Center - Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- City of Hope Comprehensive Cancer Center - Duarte
- Marin General Hospital - Greenbrae
- UC San Diego Moores Cancer Center - La Jolla
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Memorial Medical Center - Modesto
- Kaiser Permanente Oakland-Broadway - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Palo Alto Medical Foundation Health Care - Palo Alto
- Stanford Cancer Institute Palo Alto - Palo Alto
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Rohnert Park Cancer Center - Rohnert Park
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Sutter Medical Center Sacramento - Sacramento
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Banner University Medical Center - Tucson - Tucson
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2014-10 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
What the finished NCT02254278 record still lists
NCT02254278 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher).
The record links to 5 conditions, with Tongue Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02254278 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02254278 about?
NCT02254278 is a clinical study titled "Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer". This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high e...
What is the current status of trial NCT02254278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2014-10. Estimated completion is 2025-09-04.
What conditions does trial NCT02254278 study?
This clinical trial studies the following conditions: Tongue Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT02254278?
The interventions under investigation include: Cisplatin (DRUG), IMRT 6 weeks (RADIATION), IMRT 5 weeks (RADIATION).
Who is sponsoring clinical trial NCT02254278?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02254278 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tongue Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02254278's enrollment target sits among peer trials
316 155th of 2000 higher than 1,844 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia